ATYR
aTyr Pharma·NASDAQ
--
--(--)
--
--(--)
3.77 / 10
Netural
Money flow analysis registers 7.55/10, signaling robust fund inflows with positive momentum, though no clear trend is identified. Analyst consensus is neutral (100% from one analyst), and historical prediction performance is poor, contributing to an overall cautious view.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
0%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-07
InstitutionRBC Capital
Times predicted2
Historical Win Rate0.0%
What is the market sentiment for ATYR?
- ATYR holds a Bearish analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.77/10 (Netural).
